Q.Why has the Indian Parliament cleared the second amendment of the country's patents bill?
You're viewing a preview — the full solution, concept, methods & PYQ mapping are locked.
Start your 14-day free trial to unlock the full solution →The Indian Parliament cleared the second amendment to the Patents Bill primarily to comply with the World Trade Organization's TRIPS Agreement, ensuring that India's patent laws met international obligations on product patents, especially for pharmaceuticals, while safeguarding public health interests.
The story of India's Patents (Second Amendment) Bill, 2002, is not just a legal update — it is a chapter in the country's long negotiation between global trade commitments and domestic priorities. To understand why Parliament cleared this amendment, you need to step back to the early 1990s, when India signed on to the World Trade Organization (WTO) and its Agreement on Trade-Related Aspects of Intellectual Property Rights, commonly called TRIPS.
India had originally joined the WTO in 1995, and under the TRIPS Agreement, it was given a transition period — until 2005 — to bring its patent laws fully in line with international standards. The first amendment to the Patents Act, passed in 1999, was a partial step: it introduced a system for filing product patent applications in pharmaceuticals and agrochemicals, but the actual granting of those patents was deferred until 2005. The second amendment, cleared in 2002, was a much more comprehensive overhaul.
The core reason for this amendment was to meet the TRIPS deadline for introducing product patents in all fields of technology. Before this, India's patent law (the Patents Act, 1970) only allowed process patents — meaning you could patent the method of making a drug, but not the drug itself. This had allowed Indian companies to produce affordable generic versions of life-saving medicines. The TRIPS Agreement, however, required India to grant product patents as well, which would give a 20-year monopoly to the inventor of a drug, not just the process.
The 1970 Act's process-patent regime was a deliberate policy choice, rooted in India's desire to keep medicines affordable. The shift to product patents was a direct result of WTO membership, not a domestic initiative.
The 2002 amendment did several things at once. It extended patent protection to all products — including pharmaceuticals, food, and chemicals — for a uniform term of 20 years from the date of filing. It also redefined what counts as an invention, excluding discoveries, mere mixtures of known substances, and traditional knowledge from patentability. This was a crucial safeguard: India wanted to prevent companies from patenting minor modifications of existing drugs (a practice called "evergreening") or claiming ownership of ancient remedies like turmeric or neem.
Another important change was the introduction of provisions for compulsory licensing. This meant that if a patent holder did not make the product available at a reasonable price or in sufficient quantity, the government could allow another company to produce it, paying a royalty. This was India's way of balancing its TRIPS obligations with the need to protect public health — a concern that became even more prominent in later years during the HIV/AIDS crisis. …
Unlock everything free for 14 days
- Full step-by-step solutions
- Concept-first explanations
- Methods, shortcuts & mistakes
- PYQ mapping + timed mock tests
Full access for 14 days. No credit card required.